M M Moasser

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest
    M M Moasser
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 59:6145-52. 1999
  2. ncbi The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
    M M Moasser
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:7184-8. 2001
  3. ncbi The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer
    M M Moasser
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 73:135-44. 2002
  4. ncbi Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:2945-52. 2001
  5. ncbi Targeting HER proteins in cancer therapy and the role of the non-target HER3
    A C Hsieh
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
    Br J Cancer 97:453-7. 2007
  6. ncbi Targeting the function of the HER2 oncogene in human cancer therapeutics
    M M Moasser
    Department of Medicine, Comprehensive Cancer Center, University of California, San Francisco, CA 94143 0875, USA
    Oncogene 26:6577-92. 2007
  7. ncbi The epidermal growth factor receptor family: biology driving targeted therapeutics
    M J Wieduwilt
    Department of Medicine, Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143 0875, USA
    Cell Mol Life Sci 65:1566-84. 2008
  8. ncbi Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial
    C Van Poznak
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 66:239-48. 2001

Collaborators

Detail Information

Publications8

  1. ncbi Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest
    M M Moasser
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 59:6145-52. 1999
    ..This compound defines a novel class of antimitotic drugs that work through inhibition of src kinases and possibly other protein kinases that are required for progression through the initial phases of mitosis...
  2. ncbi The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
    M M Moasser
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:7184-8. 2001
    ..These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family tyrosine kinase signaling and suggest novel strategies to treat these particularly aggressive tumors...
  3. ncbi The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer
    M M Moasser
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 73:135-44. 2002
    ..Although these studies do not identify any single molecular marker that can accurately predict FTI sensitivity in breast tumors, they highlight the potential roles of FPTase activity and p53 function for further analysis...
  4. ncbi Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:2945-52. 2001
    ..G1 arrest is sufficient for some but not all aspects of the phenotype. Induction of differentiation may be responsible for some of the antitumor effects of this drug...
  5. ncbi Targeting HER proteins in cancer therapy and the role of the non-target HER3
    A C Hsieh
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
    Br J Cancer 97:453-7. 2007
    ..This review presents the current evidence highlighting the role of HER3 in tumorigenesis and its role in mediating resistance to inhibitors of EGFR and HER2...
  6. ncbi Targeting the function of the HER2 oncogene in human cancer therapeutics
    M M Moasser
    Department of Medicine, Comprehensive Cancer Center, University of California, San Francisco, CA 94143 0875, USA
    Oncogene 26:6577-92. 2007
    ..Here, I review the development of treatments that target HER2 in the context of the HER2 oncogene hypothesis, and where we stand with regards to the clinical translation of the HER2 oncogene hypothesis...
  7. ncbi The epidermal growth factor receptor family: biology driving targeted therapeutics
    M J Wieduwilt
    Department of Medicine, Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143 0875, USA
    Cell Mol Life Sci 65:1566-84. 2008
    ..Here we review the biology of ErbB receptors, including their structure, signaling, regulation, and roles in development and disease, then briefly touch on their increasing roles as targets for cancer therapy...
  8. ncbi Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial
    C Van Poznak
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 66:239-48. 2001
    ..The cell cycle regulatory effects of gossypol suggest a potential role for gossypol as a modulating agent in conjunction with other cell cycle specific compounds...